Medical aesthetics

China Resources Boya Bio-pharmaceutical Group (CR Boya) has issued a stark profit warning for 2025, forecasting net profit attributable to shareholders at RMB105 million to RMB136.5 million—a steep

China Resources Boya Bio-pharmaceutical, a key player in blood products and medical aesthetics, has alerted investors to a dramatic profit drop for 2025, forecasting net profit attributable to